Source link : https://www.newshealth.biz/health-news/doublet-immunotherapy-disappoints-in-gastric-cancer-study/
BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma, a new study shows. Results of the phase 2 AIO-STO-0417 (MOONLIGHT) trial were disappointing, given that the combination of FOLFOX and nivolumab monotherapy “has improved overall survival […]
Author : News Health
Publish date : 2024-09-14 19:32:52
Copyright for syndicated content belongs to the linked Source.
Categories